Mini-webinar: eGFR equations for multi-ethnic Asian populations

18. Mar 2024 | 6 min read

Mini-webinar: eGFR equations for multi-ethnic Asian populations

In the series of mini-webinars on cystatin C and kidney health our Global Product Manager for Cystatin C Mr. Gaute Tangen focuses on cystatin C eGFR as a potential enhancer of accuracy and reliability of estimating kidney function.

The biomarker cystatin C

Cystatin C is consistently generated and easily filtered by the kidneys. Unlike the more wieldy used biomarker creatinine, it is less affected by variables such as age, gender, or muscle mass. Consequently, incorporating cystatin C into kidney function assessments, either in conjunction with or instead of creatinine, may provide more precise estimations, especially in populations where creatinine testing may be less dependable (children, amputees, elderly, athletes).

 

Mini-webinar:
eGFR equations for multi-ethnic Asian populations

Cystatin C, alone or in combination with creatinine, provides a more accurate eGFR. Increased Cystatin C concentration is associated with an increased risk of death and end-stage renal disease across diverse populations. The study discussed in this mini-webinar seeks to assess the performance of eGFR equations in Asia, considering age groups, disease conditions, and ethnicity. Specifically, to see the performance of equations utilising creatinine and cystatin C biomarkers individually and in combination across diverse age groups and disease conditions in various Asian ethnicities.1

WATCH ON YOUTUBE

 

eGFR equations: One size does not fit all

There are several resents articles that have looked at equations for different populations, showing that one size does not fit all. One example is this article for the Pakistani population: Comparison of Pakistani CKD-EPI, new Asian-modified CKD-EPI and revised Lund-Malmö study equations in a South Asian CKD population: a study from a Pakistani CKD cohort written by the same authors as the mini-webinar above2

 

Watch other mini-webinar discussing equations for different populations:

Can cystatin C eGFR improve accuracy in kidney care?

Disparities in kidney care and the role of cystatin C

Cystatin C, Creatinine and eGFR Equations

 

validation kit cystatin c


The Gentian Cystatin C Immunoassay

The Gentian Cystatin C Immunoassay (ERM-DA471/IFCC standardised) is an open channel turbidimetric test for quantitative analysis of cystatin C in human serum and plasma. The assay received FDA 510(k) clearance in 2008. It is CE-marked and complies with the European In-Vitro Diagnostic Regulation (IVDR), EU 2017/746.

  • ERM-DA471/IFCC standardised
  • FDA510 (k) cleared
  • IVDR certified
  • Available for a wide range of clinical analysers (open channel assay)
  • Particle-Enhanced Turbidimetric Immunoassay (PETIA)
  • Rapidly performed in only 10 minutes
  • Avian antibodies – Less interference

 

Contact Gentian for more information about cystatin C

Get in touch with our Product Manager for cystatin C for product specification and pricing. Fill out the form below or send an email to marketing@gentian.com

 

 

cystatin c immunoassay

 

References: 

Safdar A et al. Optimal Glomerular Filtration Rate Equations for Various Age Groups, Disease Conditions and Ethnicities in Asia: A Systematic ReviewJ Clin Med. 2023

Safdar A et al. Comparison of Pakistani CKD-EPI, new Asian-modified CKD-EPI and revised Lund-Malmö study equations in a South Asian CKD population: a study from a Pakistani CKD cohortJ Nephrol. Published online August 30, 2023

 

CE bw

This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances.

You may also read


Cystatin C testing - Balancing additional costs against potential benefits

Apr 11, 2024

Cystatin C testing - Balancing additional costs against potential benefits

The KDIGO (Kidney Disease: Improving Global Outcomes) 2024 Clinical Practice Guideline for the Evaluation and..

Scientists to Gentian’s R&D department

Apr 08, 2024

Scientists to Gentian’s R&D department

Scientists to Gentian’s application validation group We are looking for two new colleagues in the positions..

KDIGO CKD 2024 guidelines: Patients benefiting from combined cystatin C and creatinine

Apr 03, 2024

KDIGO CKD 2024 guidelines: Patients benefiting from combined cystatin C and creatinine

The global non-profit organisation KDIGO (Kidney Disease: Improving Global Outcomes), commits to create and..